CALGARY, ALBERTA, Jan 11, 2010 (Marketwire via COMTEX) ----Stem Cell
Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) announced today
it has been advised by the Data Safety Monitoring Board ("DSMB") that its
second regularly scheduled safety analysis has been completed and the DSMB has
recommended for the Phase IIb acute ischemic stroke trial to continue as per
protocol.

Dr. Alan Moore, President and CEO, commented as follows:

"64 patients have been enrolled to-date in our modified REGENESIS Phase IIb
acute ischemic stroke study. With all of the planned clinical trial sites in
India, Canada and the U.S. recruiting patients for the Phase IIb acute ischemic
stroke trial, and continuing with the steady patient enrollment rate, we
anticipate Phase IIb patient enrollment to be complete by the end of Q1 2010
and for top-line data to be available after the 90-day patient assessment
review period is complete, approximately by the end of Q2 2010. Notably, this
remains aligned with the timeline stated in the announcement of the first
positive DSMB review on November 20, 2009."

In regard to the traumatic brain injury ("TBI") clinical trial, the Company
continues to work with Dr. David Zygun from the Department of Critical Care at
the University of Calgary, Foothills Medical Centre. The Phase IIa TBI clinical
trial is expected to begin enrolling patients in the first half of this year.

SCT is also working closely with Drs. Luanne Metz and Fiona Costello of the
Multiple Sclerosis Clinic at the Foothills Medical Centre in Calgary, Alberta
to facilitate the advancement of the multiple sclerosis clinical program.

"2010 is going to be a banner year for SCT," said Dr. Alan Moore, "and we are
working diligently to achieve a number of important company milestones that
should, in turn, translate into maximized shareholder and corporate value."

About the Data Safety Monitoring Board ("DSMB"): The DSMB is a group of
independent clinical experts that review the ongoing conduct of a clinical
trial to ensure continuing patient safety. The mandate of SCT's DSMB is to
provide objective, independent monitoring of patient safety during the Phase
IIb acute ischemic stroke trial. This review was the second of three formal
meetings scheduled that will occur over the duration of the Phase IIb stroke
trial.

Full story
http://www.foxbusiness.com/story/markets/industries/health-care/stem-cell-therapeutics-corp-announces-second-positive-review-data-safety/